BRIEF-Adamas announces FDA acceptance of ADS-5102 new drug application
January 06, 2017 at 09:08 AM EST
* Adamas announces FDA acceptance of ADS-5102 new drug application for the treatment of levodopa-induced dyskinesia in patients with parkinson's disease